Will you offer adjuvant T-DM1 for patients with HER2+ breast cancer who have residual invasive disease following neoadjuvant therapy?  

Will you incorporate the results from KATHERINE into clinical practice now?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Community Practice